 Naltrexone
"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 1 | 3 | | 2000 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2007 | 3 | 1 | 4 | | 2008 | 4 | 0 | 4 | | 2010 | 2 | 2 | 4 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 1 | 3 | | 2014 | 0 | 2 | 2 | | 2015 | 3 | 1 | 4 | | 2016 | 1 | 3 | 4 | | 2017 | 1 | 0 | 1 | | 2018 | 6 | 3 | 9 | | 2019 | 2 | 1 | 3 | | 2020 | 4 | 1 | 5 | | 2021 | 1 | 1 | 2 | | 2022 | 0 | 2 | 2 | | 2023 | 3 | 3 | 6 | | 2024 | 4 | 3 | 7 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Aug; 120(8):1634-1645.
-
Calcaterra SL, Mann S, Grimm E, Keniston A, Saunders S. Perspectives of In-Hospital Intramuscular Naltrexone and Oral Medications for Alcohol Use Disorder: A Study of Addiction Clinicians and Hospitalized Patients. J Gen Intern Med. 2025 Sep; 40(12):2981-2988.
-
Kee DP, Buyske JJ, Calcaterra SL. Things We Do for No Reason?: Avoiding naltrexone for alcohol use disorder in liver disease. J Hosp Med. 2025 Jul; 20(7):768-771.
-
Le P, Rich JJ, Bernstein EY, Glass J, Gasoyan H, Back SE, Bui TC, Rothberg MB. Disparities in Treatment for Alcohol Use Disorder Among All of Us Participants. Am J Psychiatry. 2024 Nov 01; 181(11):973-987.
-
Y Bernstein E, Magane KM, Dukes KA, Palfai TP, Lee JH, Saitz R, Samet JH. Correlates of post-hospitalization naltrexone adherence for alcohol use disorder. Drug Alcohol Depend. 2024 Dec 01; 265:112470.
-
Castry M, Tin Y, Feder NM, Lewis N, Chatterjee A, Rudorf M, Samet JH, Beers D, Medley B, Gilbert L, Linas BP, Barocas JA. An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorder. J Subst Use Addict Treat. 2024 Dec; 167:209517.
-
Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 07; 119(7):1313-1321.
-
Terasaki D, Ellinwood A, White D. Quadruple pharmacotherapy for alcohol use disorder tolerable yet insufficient: a case report. Subst Abuse Treat Prev Policy. 2024 Feb 29; 19(1):18.
-
Gibbons JB, McCullough JS, Zivin K, Brown ZY, Norton EC. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare. J Subst Use Addict Treat. 2024 02; 157:209271.
-
Radi R, Huang H, Rivera J, Lyon C, DeSanto K. Is low-dose naltrexone effective in chronic pain management? J Fam Pract. 2023 09; 72(7):320-321.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|